durvalumab + doxorubicin

Durvalumab + doxorubicin is an investigational combination therapy consisting of the anti-PD-L1 monoclonal antibody durvalumab and the anthracycline chemotherapeutic agent doxorubicin. Durvalumab is an immune checkpoint inhibitor that blocks programmed death-ligand 1 (PD-L1), thereby enhancing T-cell mediated antitumor responses. Doxorubicin intercalates DNA and inhibits topoisomerase II, leading to cytotoxicity in rapidly dividing cells. The combination aims to leverage both immunomodulatory effects and direct cytotoxicity for enhanced efficacy in cancer treatment. This regimen has been studied primarily in soft tissue sarcoma (STS) and breast cancer, showing promising efficacy with a manageable toxicity profile[1][2][3].

Other names

durvalumab plus doxorubicindurvalumab and doxorubicin